Back to MORGAN STANLEY MORGAN STANLEY

LCTXLCTX
Showing 8 of 9 quarters

Position history for MORGAN STANLEYMORGAN STANLEY's holdings in LINEAGE CELL THERAPEUTICS IN

MORGAN STANLEY holds 1.5M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), worth $1.9M as of 2026-Q2. The position was decreased (-21.3% shares). LCTX represents 0.0% of MORGAN STANLEY's portfolio.

Current Value

$1.9M

Current Shares

1.5M

Total Value Change

+$1.2M

Total Shares Change

+623,171

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
1.5M
-21.3%
$1.9M0.0%$1.31
0
2026-Q1
Decreased
1.9M
-6.5%
$3M0.0%$1.89
0
2025-Q4
Increased
2M
+98.6%
$3.3M0.0%$1.60
43
2025-Q3
Increased
1M
+20.2%
$1.7M0.0%$1.79
31
2025-Q2
Decreased
837,463
-13.6%
$759,9140.0%$0.94
0
2025-Q1
Increased
968,781
+46.8%
$437,5030.0%$0.49
22
2024-Q4
Decreased
660,061
-22.2%
$331,6800.0%$0.50
0
2024-Q3
Increased
848,291
+61.1%
$767,9580.0%$0.92
36

Other major holders of LCTX: BlackRock, Inc., VANGUARD GROUP INC, VANGUARD CAPITAL MANAGEMENT LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used